Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Employees - 125,
CEO - Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 341.83M
| Ticker | MAZE |
| Index | RUT |
| Curent Price | 7.80 |
| Change | 1.36% |
| Market Cap | 341.83M |
| Average Volume | 303.13K |
| Income | - |
| Sales | - |
| Book Value/Share | -7.11 |
| Cash/Share | 4.49 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 125 |
| Moving Avg 20days | -12.41% |
| Moving Avg 50days | -26.17% |
| Moving Avg 200days | -29.09% |
| Shares Outstanding | 43.80M |
| Earnings Date | Mar 31 BMO |
| Inst. Ownership | 13.70% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 1.74 |
| Price/FCF | - |
| Quick Ratio | 9.76 |
| Current Ratio | 9.76 |
| Debt/Equity | 0.14 |
| Return on Assets | - |
| Return on Equity | - |
| Return on Investment | - |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 38.19 |
| BETA(β) | - |
| From 52week Low | 16.32% |
| From 52week High | -54.09% |
| EPS | - |
| EPS next Year | -2.76 |
| EPS next Qtr | -0.72 |
| EPS this Year | -315.41% |
| EPS next 5 Year | - |
| EPS past 5 Year | - |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | - |
| Sales Y/Y | - |
| EPS Q/Q | - |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | -993.66% |
| ATR(14) | 1.21 |
| Perf Week | -7.19% |
| Perf Month | -27.46% |
| Perf Quarter | - |
| Perf Year | - |
| Perf YTD | -51.07% |
| Target Price | 25.67 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer